Microbiology

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

Retrieved on: 
Tuesday, September 28, 2021
PDE4, Infection, BLA, Review, USD, Metabolism, NDA, MD Anderson Cancer Center, Stock exchange, Therapy, Hidradenitis suppurativa, CMC, HKEX, Cancer, Biologics license application, Patient, NMPA, Microbiology, Population, Control, Marketing, Company, Psoriasis, Prevalence, Sintilimab, Autoimmunity, SAN, Eli Lilly and Company, Atopic dermatitis, Bevacizumab, Leo Pharma, Integrity, Research, Chemistry, Spotlight Innovation, D, Safety, Motherboard, UNION, Pharmaceutical industry

"We are very pleased to enter a collaboration with UNION.

Key Points: 
  • "We are very pleased to enter a collaboration with UNION.
  • This collaboration further strengthens our position in autoimmune by adding a mid-stage potential best-in-class therapy into our portfolio.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.
  • The company is currently working with two complementary chemistry classes, spanning immunology and microbiology with seven programs in clinical development.

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

Retrieved on: 
Tuesday, September 28, 2021
PDE4, Infection, News, Nature, BLA, Review, USD, Metabolism, NDA, MD Anderson Cancer Center, Stock exchange, Therapy, Hidradenitis suppurativa, Adalimumab, CMC, Social conditions in Honduras, HKEX, Cancer, Biologics license application, Patient, NMPA, Microbiology, Population, Control, Marketing, Environment, Company, Psoriasis, A/S, Prevalence, Sintilimab, Autoimmunity, SAN, Eli Lilly and Company, Atopic dermatitis, Bevacizumab, Leo Pharma, Integrity, Research, Chemistry, D, Safety, Motherboard, UNION, Pharmaceutical industry, Generic drug

Dr. Yongjun Liu, President of Innovent, said: "We are very pleased to enter a collaboration with UNION.

Key Points: 
  • Dr. Yongjun Liu, President of Innovent, said: "We are very pleased to enter a collaboration with UNION.
  • This collaboration further strengthens our position in autoimmune by adding a mid-stage potential best-in-class therapy into our portfolio.
  • Orismilast is a potent and selective, next-generation PDE4 inhibitor with broad anti-inflammatory properties, which was originally developed by LEO Pharma and acquired by UNION in 2020.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Elevar Therapeutics Announces New Appointments to Strengthen Its Senior Leadership Team

Retrieved on: 
Monday, September 27, 2021
Biochemistry, Mike Hopkins (basketball), Therapy, University of Illinois at Chicago College of Dentistry, Sun Pharma, Pharmacokinetics, University, School, NDA, Toxicological Sciences, Doctor of Philosophy, Patient, Microbiology, Data management, Toxicology, Royal commission, Stomach, Ovarian cancer, Pharmacology, Paclitaxel, Leadership, Biopharmaceutical, Johns Hopkins University, Public health, Jiangsu Hengrui Medicine, European Commission, Drug development, VP, SALT, Orphan drug, DMPK, Academy, Pharmaceutical industry

These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.

Key Points: 
  • These key strategic appointments will significantly strengthen our organization's drug development capabilities and clinical expertise, as we continue to build Elevar into a fully integrated biopharmaceutical company," said Maureen G. Conlan, M.D., F.A.C.P., Chief Medical Officer of Elevar Therapeutics.
  • Robert "Bob" Faulkner, Ph.D., F.C.P., F.C.C.P.joins Elevar as VP of DMPK/clinical pharmacology from Sun Pharmaceutical Industries Ltd. (Sun Pharma) where he served as senior director of clinical pharmacology & biopharmaceutics.
  • In his new role, Bob's responsibilities will span all Elevar development programs, as well as exploratory studies to support evaluation of potential pipeline expansions.
  • joins Elevar as VP of non-clinical development from Voisin Consulting Life Sciences where he served as senior director, nonclinical and early clinical development.

PacBio Partners with The European Reference Genome Atlas Initiative

Retrieved on: 
Monday, September 27, 2021
Molecule, Leibniz Association, Pacific Biosciences, Abraxis BioScience, Biodiversity, Partnership, Biomedical Research, Research, Climate, Climate change, Security (finance), Genome, Health, NASDAQ, Single-molecule real-time sequencing, U.S. Securities and Exchange Commission, Zoo, Vertebrate Genomes Project, High fidelity, Microbiology, Research group, Biology, Private Securities Litigation Reform Act, Royal commission, Genomics, EBP, Company, Program, General manager, Growth, Cataloging, Genetic variation, Risk, Horizon Europe, Earth BioGenome Project, Chair, Wellcome Sanger Institute, European Commission, EMEA, Securities Exchange Act of 1934, Acceleration, Nasdaq, GLOBE, Agriculture, Antibiotics

Biodiversity is under threat worldwide with a high number of European species at risk of extinction1.

Key Points: 
  • Biodiversity is under threat worldwide with a high number of European species at risk of extinction1.
  • Together, PacBio and ERGA aim to put Europes biodiversity on the path to recovery by 2030, said Neil Ward, Vice President and General Manager of EMEA at PacBio.
  • ERGA seeks to increase coordination across all countries of the European continent, in tandem with international partners, to generate reference-quality, complete and error-free genome assemblies for at least 200,000 plant and animal species - across Europe.
  • Were excited to welcome PacBio to the ERGA initiative and look forward to our coordinated effort to generate complete reference genomes for all European biodiversity, which will accelerate conservation initiatives and advance biodiversity genomics innovation.

Utilizing Built-In Antimicrobial Technology to Support Surface Hygiene and Cleanliness in Food Processing Environments, Webinar Presented by Microban®, Hosted by Xtalks

Retrieved on: 
Monday, September 27, 2021
Technology, Adoption, Cleanliness, BBI, Hygiene, Food, Microbiology, Fancy Ultra Fresh, Food contact materials, Regulatory affairs, Element, Bacteria, Method, Growth, Science, Asia, Industry, Food preservation

Integration of antimicrobial surfaces can support a wider approach to hygiene.

Key Points: 
  • Integration of antimicrobial surfaces can support a wider approach to hygiene.
  • Built-in antimicrobial technologies have been shown to provide durable and complementary surface protection against bacteria, mold and mildew growth.
  • These formulations become a permanent feature of a product, enabling manufacturing facilities to maintain hygienically cleaner food processing environments and working to support regular cleaning protocols.
  • For more information, or to register for this event, visit Utilizing Built-In Antimicrobial Technology to Support Surface Hygiene and Cleanliness in Food Processing Environments.

Electromed, Inc. Announces Nominations of Kathy Tune and Joe Galatowitsch as New Independent Directors

Retrieved on: 
Monday, September 27, 2021
Public Policy, Government, Healthcare Reform, Health, Consumer, Seniors, General Health, Opus, Chairperson, Record, Thomas, Microbiology, Annual Meetings of the International Monetary Fund and the World Bank Group, PAA, Business, Biomedical engineering, University, Growth, Strategic planning, Partner, Safe harbor, Investment, Medtronic, SEC, Vaccine, Board of directors, U.S. Securities and Exchange Commission, Annual general meeting, Private Securities Litigation Reform Act, McNerney, Marquette University, NYSE, Veritas Capital, Global, Marketing, Acquisition, Company, LLC, Woman, Forward-looking statement, Intellectual property, Name, 3M, Â, Pleasure, Security (finance), Intention, Patient, Housing, Communities and Local Government Committee, Board, COVID-19, MBA, Research, Minnesota State University, Mankato, Degenerative disease, Securities Exchange Act of 1934, Navigant Consulting, Management, Risk management, Kathleen A. Tune, Joseph L. Galatowitsch, Electromed, Inc., KATHLEEN A. TUNE, JOSEPH L. GALATOWITSCH, ELECTROMED, INC.

The Board will elect a new independent Chair of the Board immediately following the Annual Meeting.

Key Points: 
  • The Board will elect a new independent Chair of the Board immediately following the Annual Meeting.
  • At Electromed, we are committed to adding directors with complementary skills and capabilities that contribute toward Electromeds continued growth and generation of shareholder value.
  • I look forward to working alongside Kathy, Joe and my other fellow Board members as well as management to build on this momentum.
  • Tune is also a Managing Partner with Capita3, an early stage venture capital fund focused on women led healthcare startup founders.

Clever Culture Systems Appoints Thermo Fisher Scientific as Exclusive US APAS® Distributor

Retrieved on: 
Monday, September 27, 2021
Food, Partnership, Artificial intelligence, Intermediary, US FDA, Thermo Fisher Scientific, FDA, Workload, Microbiology, APAS, Marketing, US Foods, Food and Drug Administration, Company, Agreement, ASX, LBT, Technology, Intelligence, Automation, Maintenance, History, Laboratory, CCS, US, Fine chemical, Medical device

Agreement has a five-year term, including service and support responsibilities

Key Points: 
  • Agreement has a five-year term, including service and support responsibilities
    LBT's 50% owned joint-venture Company, Clever Culture Systems (CCS), has signed a five-year Agreement for Thermo Fisher to become the exclusive distributor for the APAS Independence in the United States.
  • Under the Agreement, Thermo Fisher will engage in sales and marketing, and related activities for the APAS Independence exclusively in the United States.
  • "We see a clear fit for the APAS Independence within our portfolio of microbiology products for the U.S. clinical market.
  • The Company's second product, the Automated Plate Assessment System (APAS) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH.

Clever Culture Systems Appoints Thermo Fisher Scientific as Exclusive US APAS® Distributor

Retrieved on: 
Monday, September 27, 2021
Food, Partnership, Artificial intelligence, Intermediary, US FDA, Thermo Fisher Scientific, FDA, Workload, Microbiology, APAS, Marketing, US Foods, Food and Drug Administration, Company, Agreement, ASX, LBT, Technology, Intelligence, Automation, Maintenance, History, Laboratory, CCS, US, Fine chemical, Medical device

Agreement has a five-year term, including service and support responsibilities

Key Points: 
  • Agreement has a five-year term, including service and support responsibilities
    LBT's 50% owned joint-venture Company, Clever Culture Systems (CCS), has signed a five-year Agreement for Thermo Fisher to become the exclusive distributor for the APAS Independence in the United States.
  • Under the Agreement, Thermo Fisher will engage in sales and marketing, and related activities for the APAS Independence exclusively in the United States.
  • "We see a clear fit for the APAS Independence within our portfolio of microbiology products for the U.S. clinical market.
  • The Company's second product, the Automated Plate Assessment System (APAS) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
Friday, September 24, 2021
Molecule, Pacific Biosciences, Biomedical Research, RSU, Financial compensation, NASDAQ, Single molecule fluorescent sequencing, Microbiology, Option, Effective date, Pacific Ocean, Genetic variation, GLOBE

MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (RSUs) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on September 20, 2021.

Key Points: 
  • MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (RSUs) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the 2020 Inducement Plan) effective on September 20, 2021.
  • The options have an exercise price of $27.99 per share, which is equal to the closing price of Pacific Biosciences common stock on September 20, 2021 (the Effective Date).
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

CAP Advances Quality in Laboratory Medicine and Safeguards Patient Testing With Annual Release of Laboratory Accreditation Program Checklists

Retrieved on: 
Thursday, September 23, 2021
Education, Health, Other Science, General Health, Research, Science, University, Microbiology, Transfusion medicine, Annual report, Accreditation, CLIA, Medicare, Medicaid, CAP, Patient, Pathology, CMS, College of American Pathologists, Medicine, Center, Technology, Clinical Laboratory, Human, Research, Laboratory, College, Marie Cassidy, Health insurance, Medical device, Property management

The CMS regulates all laboratory testing, except research, performed on humans in the US through the Clinical Laboratory Improvement Amendments (CLIA).

Key Points: 
  • The CMS regulates all laboratory testing, except research, performed on humans in the US through the Clinical Laboratory Improvement Amendments (CLIA).
  • CAP members and affiliated experts scrutinize the checklists annually, working to integrate advancements in medicine, technology, and laboratory management, said Richard Scanlan, MD, FCAP, chair, CAP Council on Accreditation, which oversees the accreditation program.
  • For 75 years, the CAP has committed itself to providing programs for laboratories to achieve the highest standards for accurate patient testing.
  • The CAP will host a webinar, 2021 CAP Accreditation Checklist Updates: Changes that Matter , for laboratory professionals to review the updates.